• Mon news: Novartis Kisqali breast cancer trial. ESMO news: Bayer, Bristol Myers, Regeneron and more. Biosecure Act fallout. Boston Scientific/Silk Road merger. See more on our front page

So who has resigned after realignment?

Looks like the 25% attrition rate they predicted/ we’re hoping for came true. People leaving from all regions but mostly from those with shitty managers. Even speciality reps getting paid more than the SSSnakes